BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Gastric cancer AND uPA AND Clinical Outcome
5 results:

  • 1. High preoperative serum vascular endothelial growth factor levels predict poor clinical outcome after curative resection of gastric cancer.
    Vidal O; Metges JP; Elizalde I; Valentíni M; Volant A; Molina R; Castells A; Pera M
    Br J Surg; 2009 Dec; 96(12):1443-51. PubMed ID: 19918848
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Her-2/neu and urokinase-type plasminogen activator and its inhibitor in breast cancer.
    Konecny G; Untch M; Arboleda J; Wilson C; Kahlert S; Boettcher B; Felber M; Beryt M; Lude S; Hepp H; Slamon D; Pegram M
    Clin Cancer Res; 2001 Aug; 7(8):2448-57. PubMed ID: 11489825
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. clinical relevance of the plasminogen activator inhibitor type 1--a multifaceted proteolytic factor.
    Harbeck N; Krüger A; Sinz S; Kates RE; Thomssen C; Schmitt M; Jänicke F
    Onkologie; 2001 Jun; 24(3):238-44. PubMed ID: 11455216
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Prognostic significance of DNA ploidy, S-phase fraction, and tissue levels of aspartic, cysteine, and serine proteases in operable gastric carcinoma.
    Russo A; Bazan V; Migliavacca M; Zanna I; Tubiolo C; Tumminello FM; Dardanoni G; Cajozzo M; Bazan P; Modica G; Latteri M; Tomasino RM; Colucci G; Gebbia N; Leto G
    Clin Cancer Res; 2000 Jan; 6(1):178-84. PubMed ID: 10656448
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Tumor-associated proteases and inhibitors in gastric cancer: analysis of prognostic impact and individual risk protease patterns.
    Allgayer H; Babic R; Grützner KU; Beyer BC; Tarabichi A; Schildberg FW; Heiss MM
    Clin Exp Metastasis; 1998 Jan; 16(1):62-73. PubMed ID: 9502078
    [TBL] [Abstract] [Full Text] [Related]  


    of 1.